Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

LONDON, Nov 19 (Reuters) - Ukraine is pushing European allies to take a political decision to release a proposed $163-billion loan based on frozen Russian state assets next month, as it frets over a ...

Ukraine's Zelenskiy ditches NATO ambition ahead of peace talks Ukraine has relinquished its ambition of joining the NATO military alliance in exchange for Western security guarantees as a compromise ...

President Volodymyr Zelenskyy said after talks with a top U.S. Army official on Thursday he was ready for "honest" work with Washington on a plan to end the war in Ukraine, while European allies ...